What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?

Alessandro Armuzzi, Alfredo Papa, Luisa Guidi, Gianluca Andrisani, Manuela Marzo, Carla Felice, Daniela Pugliese

Research output: Contribution to journalArticle

Abstract

The use of biological agents and immunomodulators for inflammatory bowel disease (IBD) is associated with an increased risk of opportunistic infections, in particular of viral or bacterial etiology. Despite the existence of international guidelines, many gastroenterologists have not adopted routine screening and vaccination in those patients with IBD, which are candidate for biologic therapy. Available strategies to screen, diagnose and prevent bacterial and viral infections in patients with IBD prior to start biological therapy are discussed in this review
Original languageEnglish
Pages (from-to)387-396
Number of pages10
JournalWORLD JOURNAL OF GASTROINTESTINAL PHARMACOLOGY AND THERAPEUTICS
Volume7
DOIs
Publication statusPublished - 2016

Keywords

  • Anti-tumor necrosis factor agents
  • Corticosteroids
  • Immunomodulators
  • Inflammatory bowel disease
  • Opportunistic infections

Fingerprint Dive into the research topics of 'What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?'. Together they form a unique fingerprint.

Cite this